Clinical Trial Details

NCT ID: NCT00552071
Date Last Changed: August 18, 2010


Research Study Summary

Patients are needed to participate in a clinical research study evaluating Sandostatin LAR for the treatment of Acromegaly

Research Study Title

Does Ultrasound-Guidance Improve the Delivery and Efficacy of Intramuscular (IM) Injection of Sandostatin LAR in the Treatment of Acromegaly


The purpose of this study is to determine the difference in drug levels of Sandostatin after IM injection of Sandostatin LAR without ultrasound guidance (as is the standard of care) compared to drug levels of Sandostatin after IM injection of Sandostatin LAR with ultrasound guidance in subjects with Acromegaly.

To Learn more

Recruitment Details

Both Male and Female
18 and up
Overall Status
Lead Sponsor
Cedars-Sinai Medical Center
41 Months
Facility Type


Both Male and Female ages 18 Years and up

Inclusion Criteria:

  • Male and female patients ≥18 years old

  • Patients with active acromegaly due to a pituitary adenoma. Historical data indicating a diagnosis of acromegaly based on circulating IGF-I concentration elevated compared to age and gender matched controls OR GH > 1 mcg/l at 120 Minutes of a two hour OGTT.

  • Currently being treated with Sandostatin LAR and have been treated with a stable dose for 3 months prior to entry into the study.

  • Patients with diabetes may be included, blood glucose and diabetic treatments are to be monitored closely during the trial in these subjects

  • Patients have provided written informed consent

Exclusion Criteria:

  • Uncontrolled diabetes mellitus

  • Patients who are pregnant or lactating

  • Patients who have a known hypersensitivity to Sandostatin acetate or other related drug or compound

  • Patients with current gallstones

  • Patients with a past or current history of cancer, except for basal cell carcinoma or in situ cancer of the cervix

  • Patients with a history of hepatic disease (patients with minimal, i.e., < 3Xs the upper limit of normal for LFTs indicative of hepatic steatosis, MAY participate)

  • Patients who have received glucocorticoid therapy within the past 6 months, or who are currently receiving any chemotherapeutic agents, or exogenous growth hormone therapy

  • Patients who have received other investigational drugs administered or received within 30 days of study entry

  • Patients with unacceptable concomitant diagnoses, or who have received medications and/or therapies (i.e., any concomitant illnesses or therapies that would place the patient at increased risk, or would, in the opinion of the investigator or sponsor, interfere with the evaluation of efficacy or safety) Interruption or discontinuation of treatment

Site Locations (1)

Country State City Zip Facility and Contact
United States California Los Angeles 90048 Cedars-Sinai Medical Center

John D Carmichael, MD
Principal Investigator

Shlomo Melmed, MD

Vivien Bonert, MD


Billy Gellepis
(310) 423-3395

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.